DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
AV-101 is an investigational drug.
There have been 4 clinical trials for AV-101. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are VistaGen Therapeutics, Inc., Michael Debakey Veterans Affairs Medical Center, and National Institute on Drug Abuse (NIDA).
There are eighteen US patents protecting this investigational drug and two hundred and thirty international patents.
Recent Clinical Trials for AV-101
|AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia||VistaGen Therapeutics, Inc.||Phase 2|
|Electrophysiological Biomarkers of AV-101||Michael Debakey Veterans Affairs Medical Center||Phase 1/Phase 2|
|Electrophysiological Biomarkers of AV-101||VistaGen Therapeutics, Inc.||Phase 1/Phase 2|
Top disease conditions for AV-101
Top clinical trial sponsors for AV-101
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AV-101||Start Trial||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||Start Trial|
|AV-101||Start Trial||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||Start Trial|
|AV-101||Start Trial||Methods for the synthesis of chiral kynurenine compounds||VISTAGEN THERAPEUTICS, INC. (South San Francisco, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|